Author Index Volume 49 (2016)
The issue number is given in front of the pagination
Aasly, J.O., see Berge, G. (2) 493–502
Abdul-Hay, S.O., see Li, H. (1) 129–137
Abizanda, P., see Salmerón, S. (1) 73–78
Agostini, S., R. Mancuso, F. Baglio, M. Cabinio, A. Hernis, F.R. Guerini, E. Calabrese, R. Nemni and M. Clerici, Lack of Evidence for a Role of HHV-6 in the Pathogenesis of Alzheimer’s Disease (1) 229–235
Ahdidan, J., C.A. Raji, E.A. DeYoe, J. Mathis, K.Ø. Noe, J. Rimestad, T.K. Kjeldsen, J. Mosegaard, J.T. Becker and O. Lopez, Quantitative Neuroimaging Software for Clinical Assessment of Hippocampal Volumes on MR Imaging (3) 723–732
Alata, W., see Do, T.M. (2) 287–300
Alvarez, M.T.B., see Shah, D.J. (2) 317–327
Ames, D., see Kinsella, G.J. (1) 31–43
Ames, D., see Zwan, M.D. (4) 1115–1122
Anand, S., see Banerjee, P. (3) 681–693
Anand, S., see Shah, D.J. (2) 317–327
Antonell, A., see Pastor, P. (2) 343–352
Aparasu, R.R., see Mehta, H.B. (2) 423–432
Apostolova, L.G., see Madhavan, A. (3) 633–643
Arancio, O., see Fà, M. (3) 707–721
Armstrong, N.J., see Wu, H.Z.Y. (3) 755–766
Arnaldi, D., see Lizio, R. (1) 159–177
Arroyo-Anlló, E.M., A.T. Bouston, M.-N. Fargeau, B.O. Baz and R. Gil, Self-Consciousness in Patients with Behavioral Variant Frontotemporal Dementia (4) 1021–1029
Ash, E.L., see Elkana, O. (3) 607–616
Assam, P.N., see Kandiah, N. (4) 1169–1177
Auff, E., see Stogmann, E. (4) 1043–1050
Babiloni, C., see Lizio, R. (1) 159–177
Baglio, F., see Agostini, S. (1) 229–235
Baiyewu, O., see Kim, S. (4) 991–1003
Banerjee, P., A. Sahoo, S. Anand, A. Bir and S. Chakrabarti, The Oral Iron Chelator, Deferasirox, Reverses the Age-Dependent Alterations in Iron and Amy-loid-β Homeostasis in Rat Brain: Implications in the Therapy of Alzheimer’s Disease (3) 681–693
Barandiarán, M., see Pastor, P. (2) 343–352
Barrado, L.G., E. Coart, H.M.J. Vanderstichele and T. Burzykowski, Transferring Cut-off Values between Assays for Cerebro-spinal Fluid Alzheimer’s Disease Biomarkers (1) 187–199
Barrado, L.G., see Rosenberger, A.F.N. (4) 927–943
Barrett, S.L., see McGuinness, B. (4) 1095–1103
Başar, E., see Lizio, R. (1) 159–177
Bayer, T.A., see Savastano, A. (1) 101–110
Baz, B.O., see Arroyo-Anlló, E.M. (4) 1021–1029
Beaufils, E., see Bouc, R.L. (4) 1075–1083
Beauregard, J.-M., see Bergeron, D. (3) 695–705
Becker, J.T., see Ahdidan, J. (3) 723–732
Beeri, M.S., see Raizes, M. (3) 589–592
Bejot, Y., see Jacquin-Piques, A. (3) 671–680
Bennett, D.A., see Han, S.D. (3) 845–851
Bennett, J., J. Burns, P. Welch and R. Bothwell, Safety and Tolerability of R(+) Pramipexole in Mild-to-Moderate Alzheimer’s Disease (4) 1179–1187
Benoit, M., see Bensamoun, D. (2) 387–398
Bensafi, M., see Joussain, P. (2) 433–441
Bensamoun, D., R. Guignard, A.J. Furst, A. Derreumaux, V. Manera, J. Darcourt, M. Benoit, P.H. Robert, R. David and for the Alzheimer’s Disease Neuroimaging Initiative, Associations between Neuropsychiatric Symptoms and Cerebral Am-yloid Deposition in Cognitively Impaired Elderly People (2) 387–398
Berge, G., C. Lauridsen, S.B. Sando, D.J. Holder, I. Møller, J.O. Aasly, G. Bråthen, M.J. Savage and L.R. White, Effect of Tween-20 on Core Biomarkers Measured in Cerebrospinal Fluid from Patients with Alzheimer’s Disease, Mild Cognitive Impairment, or Healthy Control Individuals (2) 493–502
Bergeron, D., J.-M. Beauregard, J. Guimond, M.-P. Fortin, M. Houde, S. Poulin, L. Verret, R.W. Bouchard and R. Laforce Jr., Clinical Impact of a Second FDG-PET in Atypical/Unclear Dementia Syndromes (3) 695–705
Berr, C., see Bouc, R.L. (4) 1075–1083
Berr, C., see Gabelle, A. (4) 1135–1141
Berr, C., see Pimouguet, C. (3) 819–828
Bertolino, A., see Dukart, J. (4) 1143–1159
Bertoux, M., L.C. de Souza, C. O’Callaghan, A. Greve, M. Sarazin, B. Dubois and M. Hornberger, Social Cognition Deficits: The Key to Discriminate Behavioral Variant Frontotemporal Dementia from Alzheimer’s Disease Regardless of Amnesia? (4) 1065–1074
Bessy, M., see Joussain, P. (2) 433–441
Betzale, V., see Elkana, O. (3) 607–616
Bir, A., see Banerjee, P. (3) 681–693
Bjerke, M., S. Kern, K. Blennow, H. Zetterberg, M. Waern, A. Börjesson-Hanson, S. Östling, J. Kern and I. Skoog, Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years (3) 733–741
Blennow, K., see Bjerke, M. (3) 733–741
Blennow, K., see Spiegel, J. (1) 93–100
Boada, M., see Pastor, P. (2) 343–352
Bonin-Guillaume, S., see Jacquin-Piques, A. (3) 671–680
Börjesson-Hanson, A., see Bjerke, M. (3) 733–741
Bothwell, R., see Bennett, J. (4) 1179–1187
Bouc, R.L., C. Marelli, E. Beaufils, C. Berr, C. Hommet, J. Touchon, F. Pasquier and V. Deramecourt, Limiting Factors of Brain Donation in Neurodegenerative Diseases: The Example of French Memory Clinics (4) 1075–1083
Bouchard, R.W., see Bergeron, D. (3) 695–705
Bourasset, F., see Do, T.M. (2) 287–300
Bourgeat, P., see Zwan, M.D. (4) 1115–1122
Bouston, A.T., see Arroyo-Anlló, E.M. (4) 1021–1029
Boyle, P.A., see Han, S.D. (3) 845–851
Bragason, D.T., see Einarsdottir, A.B. (1) 79–83
Brashear, H.R., see Novak, G. (4) 1123–1134
Bråthen, G., see Berge, G. (2) 493–502
Brenner, W., see Lange, C. (4) 945–959
Brewer, G.J., see LeVault, K.R. (2) 301–316
Brodaty, H., see Wu, H.Z.Y. (3) 755–766
Broecker-Preuss, M., see Dlugaj, M. (4) 1031–1042
Broecker-Preuss, M., see Winkler, A. (3) 797–807
Bruno, G., see Tosto, G. (4) 1085–1093
Buchert, R., see Lange, C. (4) 945–959
Buckley, R., see Zwan, M.D. (4) 1115–1122
Bullido, M.J., see Pastor, P. (2) 343–352
Burns, J., see Bennett, J. (4) 1179–1187
Burzykowski, T., see Barrado, L.G. (1) 187–199
Bussell, C.A., see Gavett, B.E. (2) 531–545
Butler, T., see Spiegel, J. (1) 93–100
Butterfield, D.A., see Triplett, J.C. (1) 45–62
Cabinio, M., see Agostini, S. (1) 229–235
Caga, J., see Hsieh, S. (3) 875–885
Cai, J., see Triplett, J.C. (1) 45–62
Calabrese, E., see Agostini, S. (1) 229–235
Calero, M., see Pastor, P. (2) 343–352
Calon, F., see Do, T.M. (2) 287–300
Cao, J., see Shi, Z. (2) 399–405
Cao, L., see Shan, Y. (3) 829–844
Caravaggio, F., see Chung, J.K. (3) 743–754
Carducci, F., see Lizio, R. (1) 159–177
Carp, R.I., see Lee, G.-H. (4) 1005–1019
Carro, E., see Pastor, P. (2) 343–352
Casañas-Sánchez, V., see Díaz, M. (2) 459–481
Cavedo, E., see Lizio, R. (1) 159–177
Cenina, A.R., see Kandiah, N. (4) 1169–1177
Chakrabarti, S., see Banerjee, P. (3) 681–693
Chakravarty, M.M., see Chung, J.K. (3) 743–754
Chakravarty, M.M., see Leh, S.E. (1) 237–249
Chan, Q.L., X. Xu, M.A. Shaik, S.S.T. Chong, R.J.Y. Hui, C. Li-Hsian Chen and Y. Dong, Clinical Utility of the Informant AD8 as a Dementia Case Finding Instrument in Primary Healthcare (1) 121–127
Chander, R.J., see Kandiah, N. (4) 1169–1177
Chen, H., see Mehta, H.B. (2) 423–432
Chen, S.-D., see Tang, H.-D. (4) 917–925
Chen, T.-R., see Li, F.-D. (1) 139–147
Cheong, C.Y., see Kandiah, N. (4) 1169–1177
Choi, E.-K., see Lee, G.-H. (4) 1005–1019
Choi, H.-S., see Lee, G.-H. (4) 1005–1019
Choi, S.H., see Ye, B.S. (2) 483–491
Choi, S.H., see Yoon, B. (1) 85–91
Chong, S.S.T., see Chan, Q.L. (1) 121–127
Chu, D., J. Tan, S. Xie, N. Jin, X. Yin, C.-X. Gong, K. Iqbal and F. Liu, GSK-3β is Dephosphorylated by PP2A in a Leu309 Methylation-Independent Manner (2) 365–375
Chung, J.K., E. Plitman, S. Nakajima, M.M. Chakravarty, F. Caravaggio, H. Takeuchi, P. Gerretsen, Y. Iwata, R. Patel, B.H. Mulsant, A. Graff-Guerrero and for the Alzheimer’s Disease Neuroimaging Initiative, Depressive Symptoms and Small Hippocampal Volume Accelerate the Progression to Dementia from Mild Cognitive Impairment (3) 743–754
Claassen, J.A.H.R., see van Uden, I.W.M. (3) 863–873
Clare, L., see Kinsella, G.J. (1) 31–43
Clarimón, J., see Pastor, P. (2) 343–352
Clark, C.N., J.M. Nicholas, E. Gordon, H.L. Golden, M.H. Cohen, F.J. Woodward, K. Macpherson, C.F. Slattery, C.J. Mummery, J.M. Schott, J.D. Rohrer and J.D. Warren, Altered Sense of Humor in Dementia (1) 111–119
Clegg, S., see Novak, G. (4) 1123–1134
Clerici, M., see Agostini, S. (1) 229–235
Coart, E., see Barrado, L.G. (1) 187–199
Coart, E., see Rosenberger, A.F.N. (4) 927–943
Cobell, J., see Shah, D.J. (2) 317–327
Cohen, M.H., see Clark, C.N. (1) 111–119
Collins, P., see Novak, G. (4) 1123–1134
Combarros, O., see Pastor, P. (2) 343–352
Cordone, S., see Lizio, R. (1) 159–177
Coto, E., see Pastor, P. (2) 343–352
Coutu, J.-P., A. Goldblatt, H.D. Rosas, D.H. Salat and the Alzheimer’s Disease Neuroimaging Initiative (ADNI), White Matter Changes are Associated with Ventricular Expansion in Aging, Mild Cognitive Impairment, and Alzheimer’s Disease (2) 329–342
Cui, W., see Xie, H. (4) 961–969
Cui, Y., see Liu, J. (4) 1051–1064
Da Costa Dias, B., see Pinnock, E.C. (3) 645–657
Dal-Bianco, P., see Stogmann, E. (4) 1043–1050
Darcourt, J., see Bensamoun, D. (2) 387–398
Dartigues, J.-F., see Gabelle, A. (4) 1135–1141
Dartigues, J.F., see Pimouguet, C. (3) 819–828
David, R., see Bensamoun, D. (2) 387–398
Davies, P., see Spiegel, J. (1) 93–100
de Jong, I.E.M., see Jul, P. (3) 783–795
de Laat, K.F., see van Uden, I.W.M. (3) 863–873
de Leeuw, F.-E., see van Uden, I.W.M. (3) 863–873
de Leon, M.J., see Spiegel, J. (1) 93–100
De Luca, A., see Tumminelli, G. (1) 27–30
de Munain, A.L., see Pastor, P. (2) 343–352
de Pancorbo, M.M., see Pastor, P. (2) 343–352
De Rosa, S., see Lizio, R. (1) 159–177
de Souza, L.C., see Bertoux, M. (4) 1065–1074
Del Percio, C., see Lizio, R. (1) 159–177
Dell’Agnello, G., see Dubois, B. (3) 617–631
Delphin-Combe, F., see Joussain, P. (2) 433–441
den Dunnen, W., see Rüb, U. (4) 905–915
Deramecourt, V., see Bouc, R.L. (4) 1075–1083
Derreumaux, A., see Bensamoun, D. (2) 387–398
DeYoe, E.A., see Ahdidan, J. (3) 723–732
Di Donato, I., see Tumminelli, G. (1) 27–30
Di, J., see Novak, G. (4) 1123–1134
Díaz, M., N. Fabelo, V. Casañas-Sánchez, R. Marin, T. Gómez, D. Quinto-Alemany and J.A. Pérez, Hippocampal Lipid Homeostasis in APP/PS1 Mice is Modulated by a Complex Interplay Between Dietary DHA and Estrogens: Relevance for Alzheimer’s Disease (2) 459–481
Dlugaj, M., A. Winkler, C. Weimar, J. Dürig, M. Broecker-Preuss, N. Dragano, S. Moebus, K.-H. Jöckel, R. Erbel and L. Eisele on behalf of the Heinz Nixdorf Recall Study Investigative Group, Anemia and Mild Cognitive Impairment in the German General Population (4) 1031–1042
Dlugaj, M., see Winkler, A. (3) 797–807
Do, T.M., A. Dodacki, W. Alata, F. Calon, S. Nicolic, J.-M. Scherrmann, R. Farinotti and F. Bourasset, Age-Dependent Regulation of the Blood-Brain Barrier Influx/Efflux Equilibrium of Amy-loid-β Peptide in a Mouse Model of Alzheimer’s Disease (3xTg-AD) (2) 287–300
Dobson, R.J.B., see Voyle, N. (3) 659–669
Dodacki, A., see Do, T.M. (2) 287–300
Dols-Icardo, O., see Pastor, P. (2) 343–352
Dong, Y., see Chan, Q.L. (1) 121–127
Doody, R.S., see Salmerón, S. (1) 73–78
Doraiswamy, P.M., see Kim, S. (4) 991–1003
Doré, V., see Zwan, M.D. (4) 1115–1122
Dou, F., see Geng, J. (4) 1161–1168
Dragano, N., see Dlugaj, M. (4) 1031–1042
Dragano, N., see Winkler, A. (3) 797–807
Dricot, L., see Pierrot, N. (2) 271–276
Drubach, D.A., see Madhavan, A. (3) 633–643
Duan, Y., see Liu, J. (4) 1051–1064
Dubois, B., A. Padovani, P. Scheltens, A. Rossi and G. Dell’Agnello, Timely Diagnosis for Alzheimer’s Disease: A Literature Review on Benefits and Challenges (3) 617–631
Dubois, B., see Bertoux, M. (4) 1065–1074
Duffy, J.R., see Madhavan, A. (3) 633–643
Dukart, J., F. Sambataro, A. Bertolino and for the Alzheimer’s Disease Neuroimaging Initiative, Accurate Prediction of Conversion to Alzheimer’s Disease using Imaging, Genetic, and Neuropsychological Biomarkers (4) 1143–1159
Duning, T., see Johnen, A. (3) 593–605
Dürig, J., see Dlugaj, M. (4) 1031–1042
Edwards, M., J. Hall, B. Williams, L. Johnson and S. O’Bryant, Molecular Markers of Amnestic Mild Cognitive Impair-ment among Mexican Americans (1) 221–228
Einarsdottir, A.B., S.H. Hardarson, J.V. Kristjansdottir, D.T. Bragason, J. Snaedal and E. Stefánsson, Retinal Oximetry Imaging in Alzheimer’s Disease (1) 79–83
Einstein, S., see Novak, G. (4) 1123–1134
Eisele, L., see Dlugaj, M. (4) 1031–1042
Eisikovits, O.R., see Elkana, O. (3) 607–616
Elcoroaristizabal, X., see Pastor, P. (2) 343–352
Elkana, O., O.R. Eisikovits, N. Oren, V. Betzale, N. Giladi and E.L. Ash, Sensitivity of Neuropsychological Tests to Identify Cognitive Decline in Highly Educated Elderly Individuals: 12 Months Follow up (3) 607–616
Elkana, O., see Raizes, M. (3) 589–592
Ellis, K.A., see Zwan, M.D. (4) 1115–1122
Elvang, A.B., see Jul, P. (3) 783–795
Erbel, R., see Dlugaj, M. (4) 1031–1042
Erbel, R., see Winkler, A. (3) 797–807
Fà, M., H. Zhang, A. Staniszewski, F. Saeed, L.W. Shen, I.T. Schiefer, M.I. Siklos, S. Tapadar, V.A. Litosh, J. Libien, P.A. Petukhov, A.F. Teich, G.R.J. Thatcher and O. Arancio, Novel Selective Calpain 1 Inhibitors as Potential Therapeutics in Alzheimer’s Disease (3) 707–721
Fabelo, N., see Díaz, M. (2) 459–481
Fargeau, M.-N., see Arroyo-Anlló, E.M. (4) 1021–1029
Farinotti, R., see Do, T.M. (2) 287–300
Federico, A., see Tumminelli, G. (1) 27–30
Ferdenzi, C., see Joussain, P. (2) 433–441
Fernández-Blázquez, M.Á., see Pastor, P. (2) 343–352
Fernández-Sánchez, M., see Salmerón, S. (1) 73–78
Ferreira, E., see Pinnock, E.C. (3) 645–657
Ferri, R., see Lizio, R. (1) 159–177
Flanagan, E., see Hsieh, S. (3) 875–885
Flores-Ruano, T., see Salmerón, S. (1) 73–78
Foroud, T.M., see Kim, S. (4) 991–1003
Fortea, J., see Spiegel, J. (1) 93–100
Fortin, M.-P., see Bergeron, D. (3) 695–705
Fossati, S., see Spiegel, J. (1) 93–100
Fournel, A., see Joussain, P. (2) 433–441
Fox, N., see Novak, G. (4) 1123–1134
Frank-García, A., see Pastor, P. (2) 343–352
Franko, M., see Raizes, M. (3) 589–592
Fraser, K.C., J.A. Meltzer and F. Rudzicz, Linguistic Features Identify Alzheimer’s Disease in Narrative Speech (2) 407–422
Freedberg, D.E., see Lebwohl, B. (1) 179–185
Freund, P., see Leh, S.E. (1) 237–249
Frings, L., see Lange, C. (4) 945–959
Frisoni, G.B., see Lizio, R. (1) 159–177
Frölich, L., see Koppara, A. (2) 547–560
Frommeyer, J., see Johnen, A. (3) 593–605
Fu, J., see Xie, H. (4) 961–969
Fu, Y., see Rusznák, Z. (2) 443–457
Fuchs, M., see McGuinness, B. (4) 1095–1103
Führer-Sakel, D., see Winkler, A. (3) 797–807
Fujimoto, H., see Royall, D.R. (2) 561–570
Fujimoto, H., see Royall, D.R. (2) 571–579
Fukui, K., see Royall, D.R. (2) 561–570
Fukui, K., see Royall, D.R. (2) 571–579
Furst, A.J., see Bensamoun, D. (2) 387–398
Gabelle, A., L.-A. Gutierrez, J.-F. Dartigues, K. Ritchie, J. Touchon and C. Berr, Palmomental Reflex a Relevant Sign in Early Alzheimer’s Disease Diagnosis? (4) 1135–1141
Gao, S., see Kim, S. (4) 991–1003
Gao, X., see Tang, H.-D. (4) 917–925
Gasse, C., see Nørgaard, A. (1) 211–220
Gavett, B.E., S.E. John, A.S. Gurnani, C.A. Bussell and J.L. Saurman, The Role of Alzheimer’s and Cerebrovascular Pa-thology in Mediating the Effects of Age, Race, and Apolipoprotein E Genotype on Dementia Severity in Pathologically-Confirmed Alzheimer’s Disease (2) 531–545
Geng, J., L. Xia, W. Li, C. Zhao and F. Dou, Cycloheximide Treatment Causes a ZVAD-Sensitive Protease-Dependent Cleavage of Human Tau in Drosophila Cells (4) 1161–1168
George, D.R., see Whitehouse, P.J. (1) 21–25
Gerretsen, P., see Chung, J.K. (3) 743–754
Gertz, H.-J., see Koppara, A. (2) 547–560
Gesualdo, L., see Lizio, R. (1) 159–177
Ghebremedhin, E., see Rüb, U. (4) 905–915
Gietl, A.F., see Leh, S.E. (1) 237–249
Gil, R., see Arroyo-Anlló, E.M. (4) 1021–1029
Giladi, N., see Elkana, O. (3) 607–616
Giroud, M., see Jacquin-Piques, A. (3) 671–680
Gleiss, A., see Stogmann, E. (4) 1043–1050
Glodzik, L., see Spiegel, J. (1) 93–100
Goldblatt, A., see Coutu, J.-P. (2) 329–342
Golden, H.L., see Clark, C.N. (1) 111–119
Gómez, T., see Díaz, M. (2) 459–481
Gong, C.-X., see Chu, D. (2) 365–375
Gordon, E., see Clark, C.N. (1) 111–119
Gorostidi, A., see Pastor, P. (2) 343–352
Graff-Guerrero, A., see Chung, J.K. (3) 743–754
Graves, S.W., see Shah, D.J. (2) 317–327
Green, P.H.R., see Lebwohl, B. (1) 179–185
Gregg, K., see Novak, G. (4) 1123–1134
Greve, A., see Bertoux, M. (4) 1065–1074
Grundman, M., see Novak, G. (4) 1123–1134
Guerini, F.R., see Agostini, S. (1) 229–235
Guida, V., see Tumminelli, G. (1) 27–30
Guignard, R., see Bensamoun, D. (2) 387–398
Guimond, J., see Bergeron, D. (3) 695–705
Gunter, J.L., see Madhavan, A. (3) 633–643
Gureje, O., see Kim, S. (4) 991–1003
Gurnani, A.S., see Gavett, B.E. (2) 531–545
Gutierrez, L.-A., see Gabelle, A. (4) 1135–1141
Hall, J., see Edwards, M. (1) 221–228
Hall, K.S., see Kim, S. (4) 991–1003
Halliday, G.M., see Rusznák, Z. (2) 443–457
Hameed, S., see Kandiah, N. (2) 277–285
Hampel, H., see Koppara, A. (2) 547–560
Han, S.D., P.A. Boyle, B.D. James, L. Yu and D.A. Bennett, Mild Cognitive Impairment and Susceptibility to Scams in Old Age (3) 845–851
Han, Y., see Xie, M. (2) 353–363
Hanseeuw, B., see Pierrot, N. (2) 271–276
Hansen, H.V., see Nørgaard, A. (1) 211–220
Hardarson, S.H., see Einarsdottir, A.B. (1) 79–83
Hartikainen, S., see Saarelainen, L. (3) 809–818
Haußmann, U., see Savastano, A. (1) 101–110
Hawes, S.E., see Tosto, G. (4) 1085–1093
He, F., see Li, F.-D. (1) 139–147
He, M., see Xie, H. (4) 961–969
Heinsen, H., see Rüb, U. (4) 905–915
Helboe, L., see Jul, P. (3) 783–795
Helmer, C., see Pimouguet, C. (3) 819–828
Hendrie, H.C., see Kim, S. (4) 991–1003
Henn, F., see Koppara, A. (2) 547–560
Hernandez, I., see Pastor, P. (2) 343–352
Hernis, A., see Agostini, S. (1) 229–235
Heuser, I., see Koppara, A. (2) 547–560
Hilhorst, R., see Rosenberger, A.F.N. (4) 927–943
Hock, C., see Leh, S.E. (1) 237–249
Hodges, A., see Voyle, N. (3) 659–669
Hodges, J.R., see Hsieh, S. (3) 875–885
Hodges, J.R., see Tu, S. (3) 853–861
Holder, D.J., see Berge, G. (2) 493–502
Hommet, C., see Bouc, R.L. (4) 1075–1083
Hong, C.H., see Ye, B.S. (2) 483–491
Hoozemans, J.J.M., see Rosenberger, A.F.N. (4) 927–943
Hornberger, M., see Bertoux, M. (4) 1065–1074
Hornberger, M., see Tu, S. (3) 853–861
Hou, M.-M., see Tang, H.-D. (4) 917–925
Houde, M., see Bergeron, D. (3) 695–705
Hsiao, J.-H.T., see Rusznák, Z. (2) 443–457
Hsieh, S., C.E. Leyton, J. Caga, E. Flanagan, C. Kaizik, C.M. O’Connor, M.C. Kiernan, J.R. Hodges, O. Piguet and E. Mioshi, The Evolution of Caregiver Burden in Frontotemporal Dementia with and without Amyotrophic Lateral Sclerosis (3) 875–885
Huang, S., see Xie, H. (4) 961–969
Huedo, I., see Salmerón, S. (1) 73–78
Hui, R.J.Y., see Chan, Q.L. (1) 121–127
Hüll, M., see Koppara, A. (2) 547–560
Huo, Y., see Xie, H. (4) 961–969
Indakoetxea, B., see Pastor, P. (2) 343–352
Infante, J., see Pastor, P. (2) 343–352
Iqbal, K., see Chu, D. (2) 365–375
Ivanoiu, A., see Pierrot, N. (2) 271–276
Iwata, Y., see Chung, J.K. (3) 743–754
Jack Jr, C.R., see Madhavan, A. (3) 633–643
Jacquin-Piques, A., G. Sacco, N. Tavassoli, O. Rouaud, Y. Bejot, M. Giroud, P. Robert, B. Vellas and S. Bonin-Guillaume, Psy-chotropic Drug Prescription in Patients with Dementia: Nursing Home Residents Versus Patients Living at Home (3) 671–680
Jahn, H., see Koppara, A. (2) 547–560
James, B.D., see Han, S.D. (3) 845–851
Jang, B., see Lee, G.-H. (4) 1005–1019
Jang, E.Y., see Ye, B.S. (2) 483–491
Jensen-Dahm, C., see Nørgaard, A. (1) 211–220
Jeon, Y.-C., see Lee, G.-H. (4) 1005–1019
Jeong, J.H., see Ye, B.S. (2) 483–491
Jessen, F., see Koppara, A. (2) 547–560
Jiang, T., see Liu, J. (4) 1051–1064
Jin, N., see Chu, D. (2) 365–375
Jöckel, K.-H., see Dlugaj, M. (4) 1031–1042
Jöckel, K.-H., see Winkler, A. (3) 797–807
John, S.E., see Gavett, B.E. (2) 531–545
Johnen, A., J. Frommeyer, F. Modes, H. Wiendl, T. Duning and H. Lohmann, Dementia Apraxia Test (DATE): A Brief Tool to Differentiate Behavioral Variant Frontotemporal Dementia from Alzheimer’s Dementia Based on Apraxia Profiles (3) 593–605
Johnson, J.K., see Särkämö, T. (3) 767–781
Johnson, L., see Edwards, M. (1) 221–228
Johnson, M.L., see Mehta, H.B. (2) 423–432
Johnson, W.E., see Shah, D.J. (2) 317–327
Johnston, C., see Voyle, N. (3) 659–669
Johnston, J.A., see McGuinness, B. (4) 1095–1103
Josephs, K.A., see Madhavan, A. (3) 633–643
Joussain, P., M. Bessy, A. Fournel, C. Ferdenzi, C. Rouby, F. Delphin-Combe, P. Krolak-Salmon and M. Bensafi, Altered Affective Evaluations of Smells in Alzheimer’s Disease (2) 433–441
Jovanovic, K., see Pinnock, E.C. (3) 645–657
Jul, P., C. Volbracht, I.E.M. de Jong, L. Helboe, A.B. Elvang and J.T. Pedersen, Hyperactivity with Agitative-Like Behavior in a Mouse Tauopathy Model (3) 783–795
Kaddurah-Daouk, R., see Kim, S. (4) 991–1003
Kaizik, C., see Hsieh, S. (3) 875–885
Kälin, A.M., see Leh, S.E. (1) 237–249
Kandiah, N., R.J. Chander, X. Lin, A. Ng, Y.Y. Poh, C.Y. Cheong, A.R. Cenina and P.N. Assam, Cognitive Impairment after Mild Stroke: Development and Validation of the SIGNAL2 Risk Score (4) 1169–1177
Kandiah, N., V. Wang, X. Lin, M.M. Nyu, L. Lim, A. Ng, S. Hameed and H.L. Wee, Cost Related to Dementia in the Young and the Impact of Etiological Subtype on Cost (2) 277–285
Kantarci, K., see Madhavan, A. (3) 633–643
Kato, Y., see Royall, D.R. (2) 561–570
Kato, Y., see Royall, D.R. (2) 571–579
Kauwe, J.S.K., see Shah, D.J. (2) 317–327
Keohane, A., see Voyle, N. (3) 659–669
Kern, J., see Bjerke, M. (3) 733–741
Kern, S., see Bjerke, M. (3) 733–741
Kessels, R.P.C., see van Uden, I.W.M. (3) 863–873
Khondoker, M., see Sattlecker, M. (4) 1105–1114
Kiddle, S., see Voyle, N. (3) 659–669
Kiernan, M.C., see Hsieh, S. (3) 875–885
Kim, E.-J., see Ye, B.S. (2) 483–491
Kim, H.-J., see Lee, G.-H. (4) 1005–1019
Kim, H.J., see Ye, B.S. (2) 483–491
Kim, S., K. Nho, V.K. Ramanan, D. Lai, T.M. Foroud, K. Lane, J.R. Murrell, S. Gao, K.S. Hall, F.W. Unverzagt, O. Baiyewu, A. Ogunniyi, O. Gureje, M.A. Kling, P.M. Doraiswamy, R. Kaddurah-Daouk, H.C. Hendrie and A.J. Saykin, Genetic Influences on Plasma Homocysteine Levels in African Americans and Yoruba Nigerians (4) 991–1003
Kim, S.Y., see Ye, B.S. (2) 483–491
Kim, W.S., see Rusznák, Z. (2) 443–457
Kim, Y.K., see Yoo, Y. (2) 377–386
Kim, Y.-S., see Lee, G.-H. (4) 1005–1019
King, J., see Shah, D.J. (2) 317–327
Kinsella, G.J., D. Ames, E. Storey, B. Ong, K.E. Pike, M.M. Saling, L. Clare, E. Mullaly and E. Rand, Strategies for Improving Memory: A Randomized Trial of Memory Groups for Older People, Including those with Mild Cognitive Impairment (1) 31–43
Kitagawa, K., see Miwa, K. (2) 503–513
Kjeldsen, T.K., see Ahdidan, J. (3) 723–732
Klafki, H., see Savastano, A. (1) 101–110
Klein, J.B., see Triplett, J.C. (1) 45–62
Kleineidam, L., see Koppara, A. (2) 547–560
Kling, M.A., see Kim, S. (4) 991–1003
Kłoszewska, I., see Sattlecker, M. (4) 1105–1114
Kloszewska, I., see Voyle, N. (3) 659–669
Klug, S., see Stogmann, E. (4) 1043–1050
Knackmuss, S., see Pinnock, E.C. (3) 645–657
Kollias, S., see Leh, S.E. (1) 237–249
Koponen, M., see Saarelainen, L. (3) 809–818
Koppara, A., S. Wolfsgruber, L. Kleineidam, K. Schmidtke, L. Frölich, A. Kurz, S. Schulz, H. Hampel, I. Heuser, O. Peters, F.M. Reischies, H. Jahn, C. Luckhaus, M. Hüll, H.-J. Gertz, J. Schröder, J. Pantel, O. Rienhoff, E. Rüther, F. Henn, J. Wiltfang, W. Maier, F. Jessen, J. Kornhuber and M. Wagner, The Latent Dementia Phenotype δ is Associated with Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease and Predicts Conversion to Dementia in Subjects with Mild Cognitive Impairment (2) 547–560
Korf, H.-W., see Rüb, U. (4) 905–915
Kornhuber, J., see Koppara, A. (2) 547–560
Koski, L., see Xie, H. (4) 961–969
Koumi, H., see Royall, D.R. (2) 561–570
Koumi, H., see Royall, D.R. (2) 571–579
Kristjansdottir, J.V., see Einarsdottir, A.B. (1) 79–83
Krolak-Salmon, P., see Joussain, P. (2) 433–441
Kulisevsky, J., see Pastor, P. (2) 343–352
Kurki, M., see Särkämö, T. (3) 767–781
Kurz, A., see Koppara, A. (2) 547–560
Laforce Jr., R., see Bergeron, D. (3) 695–705
Lai, D., see Kim, S. (4) 991–1003
Laitinen, S., see Särkämö, T. (3) 767–781
Lane, K., see Kim, S. (4) 991–1003
Lange, C., P. Suppa, L. Frings, W. Brenner, L. Spies, R. Buchert and for the Alzheimer’s Disease Neuroimaging Initiative, Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to- Alzheimer’s Disease Conversion (4) 945–959
Lauridsen, C., see Berge, G. (2) 493–502
Lebwohl, B., J.A. Luchsinger, D.E. Freedberg, P.H.R. Green and J.F. Ludvigsson, Risk of Dementia in Patients with Celiac Disease: A Population-Based Cohort Study (1) 179–185
Lee, G.-H., B. Jang, H.-S. Choi, H.-J. Kim, J.-H. Park, Y.-C. Jeon, R.I. Carp, Y.-S. Kim and E.-K. Choi, Upregulation of Connexin 43 Expression Via C-Jun N-Terminal Kinase Signaling in Prion Disease (4) 1005–1019
Lee, J.-H., see Ye, B.S. (2) 483–491
Lee, J.-H., see Yoo, Y. (2) 377–386
Lee, J.-Y., see Yoo, Y. (2) 377–386
Lee, S.E., see Pastor, P. (2) 343–352
Lee, Y., see Ye, B.S. (2) 483–491
Leffondré, K., see Pimouguet, C. (3) 819–828
Le-Goff, M., see Pimouguet, C. (3) 819–828
Leh, S.E., A.M. Kälin, C. Schroeder, M.T.M. Park, M.M. Chakravarty, P. Freund, A.F. Gietl, F. Riese, S. Kollias, C. Hock and L. Michels, Volumetric and Shape Analysis of the Thalamus and Striatum in Amnestic Mild Cognitive Impairment (1) 237–249
Lehrner, J., see Stogmann, E. (4) 1043–1050
Leissring, M.A., see Li, H. (1) 129–137
Lennarz, M., see Pastor, P. (2) 343–352
LeVault, K.R., S.A. Tischkau and G.J. Brewer, Circadian Disruption Reveals a Correlation of an Oxidative GSH/GSSG Redox Shift with Learning and Impaired Memory in an Alzheimer’s Disease Mouse Model (2) 301–316
Leyton, C.E., see Hsieh, S. (3) 875–885
Leyton, C.E., see Tu, S. (3) 853–861
Lhommel, R., see Pierrot, N. (2) 271–276
Li, C., see Shi, Z. (2) 399–405
Li, F.-D., F. He, T.-R. Chen, Y.-Y. Xiao, S.-T. Lin, W. Shen, X.-Y. Wang, Y.-J. Zhai, X.-P. Shang and J.-F. Lin, Reproductive History and Risk of Cognitive Impairment in Elderly Women: A Cross-Sectional Study in Eastern China (1) 139–147
Li, H., H. Zhu, M. Wallack, M. Mwamburi, S.O. Abdul-Hay, M.A. Leissring and W.Q. Qiu, Age and Its Association with Low Insulin and High Amy-loid-β Peptides in Blood (1) 129–137
Li, K., see Liu, J. (4) 1051–1064
Li, W., see Geng, J. (4) 1161–1168
Li, Y., see Spiegel, J. (1) 93–100
Li, Y., see Xie, H. (4) 961–969
Liang, L., see Tang, H.-D. (4) 917–925
Liao, X., see Xie, M. (2) 353–363
Libien, J., see Fà, M. (3) 707–721
Li-Hsian Chen, C., see Chan, Q.L. (1) 121–127
Lim, L., see Kandiah, N. (2) 277–285
Lin, J.-F., see Li, F.-D. (1) 139–147
Lin, S.-T., see Li, F.-D. (1) 139–147
Lin, X., see Kandiah, N. (2) 277–285
Lin, X., see Kandiah, N. (4) 1169–1177
Litosh, V.A., see Fà, M. (3) 707–721
Little, M., see Pinnock, E.C. (3) 645–657
Liu, B., see Liu, J. (4) 1051–1064
Liu, E., see Novak, G. (4) 1123–1134
Liu, F., see Chu, D. (2) 365–375
Liu, G., J.G. Weinger, Z.-L. Lu, F. Xue and S. Sadeghpour, Efficacy and Safety of MMFS-01, a Synapse Density Enhancer, for Treating Cognitive Impairment in Older Adults: A Randomized, Double-Blind, Placebo-Controlled Trial (4) 971–990
Liu, G., see Sun, X. (1) 63–72
Liu, J., X. Zhang, C. Yu, Y. Duan, J. Zhuo, Y. Cui, B. Liu, K. Li, T. Jiang and Y. Liu, Impaired Parahippocampus Connectivity in Mild Cognitive Impairment and Alzheimer’s Disease (4) 1051–1064
Liu, R., see Pan, Y. (1) 1–12
Liu, Y., see Liu, J. (4) 1051–1064
Liu, Y.-S., see Shan, Y. (3) 829–844
Lizio, R., C. Del Percio, N. Marzano, A. Soricelli, G.G. Yener, E. Başar, C. Mundi, S. De Rosa, A.I. Triggiani, R. Ferri, D. Arnaldi, F.M. Nobili, S. Cordone, S. Lopez, F. Carducci, G. Santi, L. Gesualdo, P.M. Rossini, E. Cavedo, M. Mauri, G.B. Frisoni and C. Babiloni, Neurophysiological Assessment of Alzheimer’s Disease Individuals by a Single Electroencephalographic Marker (1) 159–177
Lleó, A., see Pastor, P. (2) 343–352
Lohmann, H., see Johnen, A. (3) 593–605
Lopez, O., see Ahdidan, J. (3) 723–732
Lopez, S., see Lizio, R. (1) 159–177
López-Utiel, M., see Salmerón, S. (1) 73–78
Lorenzo, E., see Pastor, P. (2) 343–352
Lovestone, S., see Sattlecker, M. (4) 1105–1114
Lovestone, S., see Voyle, N. (3) 659–669
Lowe, V.J., see Madhavan, A. (3) 633–643
Lu, Y., see Novak, G. (4) 1123–1134
Lu, Z.-L., see Liu, G. (4) 971–990
Luchsinger, J.A., see Lebwohl, B. (1) 179–185
Luckhaus, C., see Koppara, A. (2) 547–560
Ludvigsson, J.F., see Lebwohl, B. (1) 179–185
Lunnon, K., see Voyle, N. (3) 659–669
Ma, J.-F., see Tang, H.-D. (4) 917–925
Ma, R., see Sun, X. (1) 63–72
Macaulay, S.L., see Zwan, M.D. (4) 1115–1122
Machulda, M.M., see Madhavan, A. (3) 633–643
Macpherson, K., see Clark, C.N. (1) 111–119
Madhavan, A., C.G. Schwarz, J.R. Duffy, E.A. Strand, M.M. Machulda, D.A. Drubach, K. Kantarci, S.A. Przybelski, R.I. Reid, M.L. Senjem, J.L. Gunter, L.G. Apostolova, V.J. Lowe, R.C. Petersen, C.R. Jack Jr, K.A. Josephs and J.L. Whitwell, Char-acterizing White Matter Tract Degeneration in Syndromic Variants of Alzheimer’s Disease: A Diffusion Tensor Im-aging Study (3) 633–643
Maier, W., see Koppara, A. (2) 547–560
Maier, W., see Pastor, P. (2) 343–352
Mäkelä, M., A. Paetau, T. Polvikoski, L. Myllykangas and M. Tanskanen, Capillary Amy-loid-β Protein Deposition in a Population-Based Study (Vantaa 85+) (1) 149–157
Maloteaux, J.-M., see Pierrot, N. (2) 271–276
Mancuso, R., see Agostini, S. (1) 229–235
Manera, V., see Bensamoun, D. (2) 387–398
Marelli, C., see Bouc, R.L. (4) 1075–1083
Margison, L., see Zwan, M.D. (4) 1115–1122
Marin, R., see Díaz, M. (2) 459–481
Martins, R., see Zwan, M.D. (4) 1115–1122
Marzano, N., see Lizio, R. (1) 159–177
Masters, C.L., see Zwan, M.D. (4) 1115–1122
Mather, K., see Wu, H.Z.Y. (3) 755–766
Mathis, J., see Ahdidan, J. (3) 723–732
Matsuoka, T., see Royall, D.R. (2) 561–570
Matsuoka, T., see Royall, D.R. (2) 571–579
Mauri, M., see Lizio, R. (1) 159–177
Mayeux, R., see Tosto, G. (4) 1085–1093
McGuinness, B., M. Fuchs, S.L. Barrett, A.P. Passmore and J.A. Johnston, Platelet Membrane β-Secretase Activity in Mild Cognitive Impairment and Conversion to Dementia: a Longitudinal Study (4) 1095–1103
Mearow, K.M., see Nafar, F. (1) 251–263
Mecocci, P., see Sattlecker, M. (4) 1105–1114
Mecocci, P., see Voyle, N. (3) 659–669
Mehta, H.B., V. Mehta, C.-L. Tsai, H. Chen, R.R. Aparasu and M.L. Johnson, Development and Validation of the RxDx-Dementia Risk Index to Predict Dementia in Patients with Type 2 Diabetes and Hypertension (2) 423–432
Mehta, V., see Mehta, H.B. (2) 423–432
Meltzer, J.A., see Fraser, K.C. (2) 407–422
Michels, L., see Leh, S.E. (1) 237–249
Mimura, M., see Royall, D.R. (2) 561–570
Mimura, M., see Royall, D.R. (2) 571–579
Mioshi, E., see Hsieh, S. (3) 875–885
Miwa, K., M. Tanaka, S. Okazaki, Y. Yagita, M. Sakaguchi, H. Mochizuki and K. Kitagawa, Increased Total Homocysteine Lev-els Predict the Risk of Incident Dementia Independent of Cerebral Small-Vessel Diseases and Vascular Risk Factors (2) 503–513
Mochizuki, H., see Miwa, K. (2) 503–513
Modes, F., see Johnen, A. (3) 593–605
Moebus, S., see Dlugaj, M. (4) 1031–1042
Moebus, S., see Winkler, A. (3) 797–807
Møller, I., see Berge, G. (2) 493–502
Monsell, S.E., see Tosto, G. (4) 1085–1093
Moreno, F., see Pastor, P. (2) 343–352
Mosegaard, J., see Ahdidan, J. (3) 723–732
Moser, D., see Stogmann, E. (4) 1043–1050
Mullaly, E., see Kinsella, G.J. (1) 31–43
Muller, P., see Savastano, A. (1) 101–110
Mulsant, B.H., see Chung, J.K. (3) 743–754
Mummery, C.J., see Clark, C.N. (1) 111–119
Mundi, C., see Lizio, R. (1) 159–177
Murrell, J.R., see Kim, S. (4) 991–1003
Mwamburi, M., see Li, H. (1) 129–137
Myllykangas, L., see Mäkelä, M. (1) 149–157
Na, D.L., see Ye, B.S. (2) 483–491
Na, H.R., see Ye, B.S. (2) 483–491
Nafar, F., J.B. Williams and K.M. Mearow, Astrocytes Release HspB1 in Response to Amy-loid-β Exposure in vitro (1) 251–263
Naji, F., see Rosenberger, A.F.N. (4) 927–943
Nakaaki, S., see Royall, D.R. (2) 561–570
Nakaaki, S., see Royall, D.R. (2) 571–579
Nakajima, S., see Chung, J.K. (3) 743–754
Nakamura, K., see Royall, D.R. (2) 561–570
Nakamura, K., see Royall, D.R. (2) 571–579
Narumoto, J., see Royall, D.R. (2) 561–570
Narumoto, J., see Royall, D.R. (2) 571–579
Nemni, R., see Agostini, S. (1) 229–235
Newhouse, S., see Voyle, N. (3) 659–669
Ng, A., see Kandiah, N. (2) 277–285
Ng, A., see Kandiah, N. (4) 1169–1177
Nho, K., see Kim, S. (4) 991–1003
Nicholas, J.M., see Clark, C.N. (1) 111–119
Nicolic, S., see Do, T.M. (2) 287–300
Nielsen, C., see Novak, G. (4) 1123–1134
Nobili, F.M., see Lizio, R. (1) 159–177
Noe, K.Ø., see Ahdidan, J. (3) 723–732
Noguerón, A., see Salmerón, S. (1) 73–78
Nørgaard, A., C. Jensen-Dahm, C. Gasse, H.V. Hansen and G. Waldemar, Time Trends in Antipsychotic Drug Use in Pa-tients with Dementia: A Nationwide Study (1) 211–220
Norris, D.G., see van Uden, I.W.M. (3) 863–873
Novak, G., N. Fox, S. Clegg, C. Nielsen, S. Einstein, Y. Lu, I.C. Tudor, K. Gregg, J. Di , P. Collins, B.T. Wyman, E. Yuen, M. Grundman, H.R. Brashear and E. Liu, Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer’s Disease (4) 1123–1134
Numminen, A., see Särkämö, T. (3) 767–781
Nyu, M.M., see Kandiah, N. (2) 277–285
O’Bryant, S., see Edwards, M. (1) 221–228
O’Callaghan, C., see Bertoux, M. (4) 1065–1074
O’Connor, C.M., see Hsieh, S. (3) 875–885
O’Leary, V.B., see Ovsepian, S.V. (1) 13–19
Oberstein, T.J., see Savastano, A. (1) 101–110
Octave, J.-N., see Pierrot, N. (2) 271–276
Ogawa, M., see Royall, D.R. (2) 561–570
Ogawa, M., see Royall, D.R. (2) 571–579
Ogunniyi, A., see Kim, S. (4) 991–1003
Okamura, A., see Royall, D.R. (2) 561–570
Okamura, A., see Royall, D.R. (2) 571–579
Okazaki, S., see Miwa, K. (2) 503–513
Ong, B., see Kinsella, G.J. (1) 31–43
Ong, K.L., see Wu, H.Z.Y. (3) 755–766
Oren, N., see Elkana, O. (3) 607–616
Ortega-Cubero, S., see Pastor, P. (2) 343–352
Osorio, R.S., see Spiegel, J. (1) 93–100
Östling, S., see Bjerke, M. (3) 733–741
Ovsepian, S.V. and V.B. O’Leary, Neuronal Activity and Amyloid Plaque Pathology: An Update (1) 13–19
Padovani, A., see Dubois, B. (3) 617–631
Paetau, A., see Mäkelä, M. (1) 149–157
Palmer, R.F. and D.R. Royall, Future Dementia Severity is Almost Entirely Explained by the Latent Variable δ’s Intercept and Slope (2) 521–529
Palmer, R.F., see Royall, D.R. (2) 561–570
Palmer, R.F., see Royall, D.R. (2) 571–579
Pan, B., see Pan, Y. (1) 1–12
Pan, Y., R. Liu, E. Terpstra, Y. Wang, F. Qiao, J. Wang, Y. Tong and B. Pan, Dysregulation and Diagnostic Potential of microRNA in Alzheimer’s Disease (1) 1–12
Pantel, J., see Koppara, A. (2) 547–560
Park, H.-K., see Yoon, B. (1) 85–91
Park, J.-H., see Lee, G.-H. (4) 1005–1019
Park, M.T.M., see Leh, S.E. (1) 237–249
Park, S., see Yoo, Y. (2) 377–386
Park, S.A., see Ye, B.S. (2) 483–491
Park, S.A., see Yoon, B. (1) 85–91
Pasquier, F., see Bouc, R.L. (4) 1075–1083
Passmore, A.P., see McGuinness, B. (4) 1095–1103
Pastor, M.A., see Pastor, P. (2) 343–352
Pastor, P., F. Moreno, J. Clarimón, A. Ruiz, O. Combarros, M. Calero, A.L. de Munain, M.J. Bullido, M.M. de Pancorbo, E. Carro, A. Antonell, E. Coto, S. Ortega-Cubero, I. Hernandez, L. Tárraga, M. Boada, A. Lleó, O. Dols-Icardo, J. Kulisevsky, J.L. Vázquez-Higuera, J. Infante, A. Rábano, M.Á. Fernández-Blázquez, M. Valentí, B. Indakoetxea, M. Barandiarán, A. Gorostidi, A. Frank-García, I. Sastre, E. Lorenzo, M.A. Pastor, X. Elcoroaristizabal, M. Lennarz, W. Maier, A. Rámirez, M. Serrano-Ríos, S.E. Lee, P. Sánchez-Juan and on behalf of The Dementia Genetic Spanish Consortium (DEGESCO), MAPT H1 Haplotype is Associated with Late-Onset Alzheimer’s Disease Risk in APOE ɛ4 Noncarriers: Results from the Dementia Genetics Spanish Consortium (2) 343–352
Patel, R., see Chung, J.K. (3) 743–754
Paxinos, G., see Rusznák, Z. (2) 443–457
Pedersen, J.T., see Jul, P. (3) 783–795
Penny, C., see Pinnock, E.C. (3) 645–657
Pérès, K., see Pimouguet, C. (3) 819–828
Pérez, J.A., see Díaz, M. (2) 459–481
Peters, O., see Koppara, A. (2) 547–560
Petersen, R.C., see Madhavan, A. (3) 633–643
Petukhov, P.A., see Fà, M. (3) 707–721
Pierrot, N., R. Lhommel, L. Quenon, B. Hanseeuw, L. Dricot, C. Sindic, J.-M. Maloteaux, J.-N. Octave and A. Ivanoiu, Targretin Improves Cognitive and Biological Markers in a Patient with Alzheimer’s Disease (2) 271–276
Piguet, O., see Hsieh, S. (3) 875–885
Piguet, O., see Tu, S. (3) 853–861
Pike, K.E., see Kinsella, G.J. (1) 31–43
Pimouguet, C., M. Le-Goff, D. Rizzuto, C. Berr, K. Leffondré, K. Pérès, J.F. Dartigues and C. Helmer, Effect of Early Referral to Specialist in Dementia on Institutionalization and Functional Decline: Findings from a Popula-tion-Based Study (3) 819–828
Pinnock, E.C., K. Jovanovic, M.G. Pinto, E. Ferreira, B. Da Costa Dias, C. Penny, S. Knackmuss, U. Reusch, M. Little, H.M. Schatzl and S.F.T. Weiss, LRP/LR Antibody Mediated Rescuing of Amy-loid-β-Induced Cytotoxicity is Dependent on PrPc in Alzheimer’s Disease (3) 645–657
Pinto, M.G., see Pinnock, E.C. (3) 645–657
Pirraglia, E., see Spiegel, J. (1) 93–100
Plitman, E., see Chung, J.K. (3) 743–754
Poh, Y.Y., see Kandiah, N. (4) 1169–1177
Polvikoski, T., see Mäkelä, M. (1) 149–157
Poulin, S., see Bergeron, D. (3) 695–705
Proitsi, P., see Sattlecker, M. (4) 1105–1114
Przybelski, S.A., see Madhavan, A. (3) 633–643
Pusswald, G., see Stogmann, E. (4) 1043–1050
Qiao, F., see Pan, Y. (1) 1–12
Qiao, Y., see Tang, H.-D. (4) 917–925
Qiu, W.Q., see Li, H. (1) 129–137
Quenon, L., see Pierrot, N. (2) 271–276
Quinto-Alemany, D., see Díaz, M. (2) 459–481
Rábano, A., see Pastor, P. (2) 343–352
Raizes, M., O. Elkana, M. Franko, R.R. Springer, S. Segev and M.S. Beeri, Higher Fasting Plasma Glucose Levels, within the Normal Range, are Associated with Decreased Processing Speed in High Functioning Young Elderly (3) 589–592
Raji, C.A., see Ahdidan, J. (3) 723–732
Ramanan, V.K., see Kim, S. (4) 991–1003
Rámirez, A., see Pastor, P. (2) 343–352
Rand, E., see Kinsella, G.J. (1) 31–43
Randall, C., see Spiegel, J. (1) 93–100
Rantanen, P., see Särkämö, T. (3) 767–781
Reid, R.I., see Madhavan, A. (3) 633–643
Reischies, F.M., see Koppara, A. (2) 547–560
Rembach, A., see Zwan, M.D. (4) 1115–1122
Reusch, U., see Pinnock, E.C. (3) 645–657
Rienhoff, O., see Koppara, A. (2) 547–560
Riese, F., see Leh, S.E. (1) 237–249
Rimestad, J., see Ahdidan, J. (3) 723–732
Ritchie, K., see Gabelle, A. (4) 1135–1141
Rizzuto, D., see Pimouguet, C. (3) 819–828
Robert, P., see Jacquin-Piques, A. (3) 671–680
Robert, P.H., see Bensamoun, D. (2) 387–398
Rohlfing, F., see Shah, D.J. (2) 317–327
Rohrer, J.D., see Clark, C.N. (1) 111–119
Rosas, H.D., see Coutu, J.-P. (2) 329–342
Rosenberger, A.F.N., R. Hilhorst, E. Coart, L.G. Barrado, F. Naji, A.J.M. Rozemuller, W.M. van der Flier, P. Scheltens, J.J.M. Hoozemans and S.M. van der Vies, Protein Kinase Activity Decreases with Higher Braak Stages of Alzheimer’s Disease Pathology (4) 927–943
Rossi, A., see Dubois, B. (3) 617–631
Rossini, P.M., see Lizio, R. (1) 159–177
Rouaud, O., see Jacquin-Piques, A. (3) 671–680
Rouby, C., see Joussain, P. (2) 433–441
Rowe, C.C., see Zwan, M.D. (4) 1115–1122
Royall, D.R., R.F. Palmer, T. Matsuoka, Y. Kato, S. Taniguchi, M. Ogawa, H. Fujimoto, A. Okamura, K. Shibata, K. Nakamura, S. Nakaaki, H. Koumi, M. Mimura, K. Fukui and J. Narumoto, δ Scores are Exportable Across Cultural and Lin-guistic Boundaries (2) 561–570
Royall, D.R., R.F. Palmer, T. Matsuoka, Y. Kato, S. Taniguchi, M. Ogawa, H. Fujimoto, A. Okamura, K. Shibata, K. Nakamura, S. Nakaaki, H. Koumi, M. Mimura, K. Fukui and J. Narumoto, Greater than the Sum of Its Parts: δ can be Con-structed from Item Level Data (2) 571–579
Royall, D.R., see Palmer, R.F. (2) 521–529
Royall, D.R., Welcome Back to Your Future: The Assessment of Dementia by the Latent Variable “δ” (2) 515–519
Rozemuller, A.J.M., see Rosenberger, A.F.N. (4) 927–943
Rüb, U., K. Stratmann, H. Heinsen, D.D. Turco, E. Ghebremedhin, K. Seidel, W. den Dunnen and H.-W. Korf, Hierarchical Distribution of the Tau Cytoskeletal Pathology in the Thalamus of Alzheimer’s Disease Patients (4) 905–915
Rudzicz, F., see Fraser, K.C. (2) 407–422
Rufa, A., see Tumminelli, G. (1) 27–30
Ruiz, A., see Pastor, P. (2) 343–352
Rusznák, Z., W.S. Kim, J.-H.T. Hsiao, G.M. Halliday, G. Paxinos and Y. Fu, Early in vivo Effects of the Hu-man Mutant Amy-loid-β Protein Precursor (hAβPPSwInd) on the Mouse Olfactory Bulb (2) 443–457
Rüther, E., see Koppara, A. (2) 547–560
Rutten-Jacobs, L.C.A., see van Uden, I.W.M. (3) 863–873
Saarelainen, L., H. Taipale, M. Koponen, A. Tanskanen, A.-M. Tolppanen, J. Tiihonen and S. Hartikainen, The Incidence of Benzodiazepine and Related Drug Use in Persons with and without Alzheimer’s Disease (3) 809–818
Sacco, G., see Jacquin-Piques, A. (3) 671–680
Sachdev, P., see Wu, H.Z.Y. (3) 755–766
Sadeghpour, S., see Liu, G. (4) 971–990
Saeed, F., see Fà, M. (3) 707–721
Sahoo, A., see Banerjee, P. (3) 681–693
Saint Louis, L.A., see Spiegel, J. (1) 93–100
Sakaguchi, M., see Miwa, K. (2) 503–513
Salat, D.H., see Coutu, J.-P. (2) 329–342
Saling, M.M., see Kinsella, G.J. (1) 31–43
Salmerón, S., I. Huedo, M. López-Utiel, I. Soler-Moratalla, T. Flores-Ruano, M. Fernández-Sánchez, A. Noguerón, R.S. Doody and P. Abizanda, Validation of the Spanish Version of the Baylor Profound Mental Status Examination (1) 73–78
Salvado, O., see Zwan, M.D. (4) 1115–1122
Sambataro, F., see Dukart, J. (4) 1143–1159
Sánchez-Juan, P., see Pastor, P. (2) 343–352
Sando, S.B., see Berge, G. (2) 493–502
Santi, G., see Lizio, R. (1) 159–177
Sarazin, M., see Bertoux, M. (4) 1065–1074
Särkämö, T., S. Laitinen, A. Numminen, M. Kurki, J.K. Johnson and P. Rantanen, Clinical and Demographic Factors Associated with the Cognitive and Emotional Efficacy of Regular Musical Activities in Dementia (3) 767–781
Sastre, I., see Pastor, P. (2) 343–352
Sattlecker, M., M. Khondoker, P. Proitsi, S. Williams, H. Soininen, I. Kłoszewska, P. Mecocci, M. Tsolaki, B. Vellas and S. Lovestone on behalf of the AddNeuroMed Consortium and Richard JB Dobson, Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer’s Disease (4) 1105–1114
Saurman, J.L., see Gavett, B.E. (2) 531–545
Savage, M.J., see Berge, G. (2) 493–502
Savastano, A., H. Klafki, U. Haußmann, T.J. Oberstein, P. Muller, O. Wirths, J. Wiltfang and T.A. Bayer, N-Truncated Aβ2-X Starting with Position Two in Sporadic Alzheimer’s Disease Cases and Two Alzheimer Mouse Models (1) 101–110
Saykin, A.J., see Kim, S. (4) 991–1003
Schatzl, H.M., see Pinnock, E.C. (3) 645–657
Scheltens, P., see Dubois, B. (3) 617–631
Scheltens, P., see Rosenberger, A.F.N. (4) 927–943
Scheltens, P., see Zwan, M.D. (4) 1115–1122
Scherrmann, J.-M., see Do, T.M. (2) 287–300
Schiefer, I.T., see Fà, M. (3) 707–721
Schmidtke, K., see Koppara, A. (2) 547–560
Schott, J.M., see Clark, C.N. (1) 111–119
Schreurs, B.G. and D.L. Sparks, Dietary High Cholesterol and Trace Metals in the Drinking Water Increase Levels of ABCA1 in the Rabbit Hippocampus and Temporal Cortex (1) 201–209
Schröder, J., see Koppara, A. (2) 547–560
Schroeder, C., see Leh, S.E. (1) 237–249
Schulz, S., see Koppara, A. (2) 547–560
Schwarz, C.G., see Madhavan, A. (3) 633–643
Seeher, K., see Wu, H.Z.Y. (3) 755–766
Segev, S., see Raizes, M. (3) 589–592
Seidel, K., see Rüb, U. (4) 905–915
Senjem, M.L., see Madhavan, A. (3) 633–643
Seo, S.W., see Ye, B.S. (2) 483–491
Serrano-Ríos, M., see Pastor, P. (2) 343–352
Shah, D.J., F. Rohlfing, S. Anand, W.E. Johnson, M.T.B. Alvarez, J. Cobell, J. King, S.A. Young, J.S.K. Kauwe and S.W. Graves, Discovery and Subsequent Confirmation of Novel Serum Biomarkers Diagnosing Alzheimer’s Disease (2) 317–327
Shaik, M.A., see Chan, Q.L. (1) 121–127
Shan, Y., D.-D. Wang, Y.-X. Xu, C. Wang, L. Cao, Y.-S. Liu and C.-Q. Zhu, Aging as a Precipitating Factor in Chronic Restraint Stress-Induced Tau Aggregation Pathology, and the Protective Effects of Rosmarinic Acid (3) 829–844
Shang, X., see Sun, X. (1) 63–72
Shang, X.-P., see Li, F.-D. (1) 139–147
Shen, L.W., see Fà, M. (3) 707–721
Shen, W., see Li, F.-D. (1) 139–147
Shen, Y., see Shi, Z. (2) 399–405
Shi, X., see Xie, H. (4) 961–969
Shi, Z., Y. Zhu, M. Wang, Y. Wu, J. Cao, C. Li, Z. Xie and Y. Shen, The Utilization of Retinal Nerve Fiber Layer Thickness to Predict Cognitive Deterioration (2) 399–405
Shibata, K., see Royall, D.R. (2) 561–570
Shibata, K., see Royall, D.R. (2) 571–579
Shim, Y.S., see Yoon, B. (1) 85–91
Shin, S.A., see Yoo, Y. (2) 377–386
Siklos, M.I., see Fà, M. (3) 707–721
Sindic, C., see Pierrot, N. (2) 271–276
Skoog, I., see Bjerke, M. (3) 733–741
Slattery, C.F., see Clark, C.N. (1) 111–119
Snaedal, J., see Einarsdottir, A.B. (1) 79–83
Soininen, H., see Sattlecker, M. (4) 1105–1114
Soininen, H., see Voyle, N. (3) 659–669
Soler-Moratalla, I., see Salmerón, S. (1) 73–78
Soricelli, A., see Lizio, R. (1) 159–177
Sparks, D.L., see Schreurs, B.G. (1) 201–209
Spiegel, J., E. Pirraglia, R.S. Osorio, L. Glodzik, Y. Li, W. Tsui, L.A. Saint Louis, C. Randall, T. Butler, J. Xu, R.P. Zinkowski, H. Zetterberg, J. Fortea, S. Fossati, T. Wisniewski, P. Davies, K. Blennow and M.J. de Leon, Greater Specificity for Cerebrospinal Fluid P-tau231 over P-tau181 in the Differentiation of Healthy Controls from Alzheimer’s Disease (1) 93–100
Spies, L., see Lange, C. (4) 945–959
Springer, R.R., see Raizes, M. (3) 589–592
Staniszewski, A., see Fà, M. (3) 707–721
Stefánsson, E., see Einarsdottir, A.B. (1) 79–83
Stogmann, E., D. Moser, S. Klug, A. Gleiss, E. Auff, P. Dal-Bianco, G. Pusswald and J. Lehrner, Activities of Daily Living and Depressive Symptoms in Patients with Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer’s Disease (4) 1043–1050
Storey, E., see Kinsella, G.J. (1) 31–43
Strand, E.A., see Madhavan, A. (3) 633–643
Stratmann, K., see Rüb, U. (4) 905–915
Sun, X., R. Ma, X. Yao, X. Shang, Q. Wang, J.-Z. Wang and G. Liu, Concanavalin Agglutinin Levels are Decreased in Peripheral Blood of Alzheimer’s Disease Patients (1) 63–72
Suppa, P., see Lange, C. (4) 945–959
Swomley, A.M., see Triplett, J.C. (1) 45–62
Taipale, H., see Saarelainen, L. (3) 809–818
Takeuchi, H., see Chung, J.K. (3) 743–754
Tan, J., see Chu, D. (2) 365–375
Tanaka, M., see Miwa, K. (2) 503–513
Tang, G., see Xie, H. (4) 961–969
Tang, H.-D., Y. Zhou, X. Gao, L. Liang, M.-M. Hou, Y. Qiao, J.-F. Ma and S.-D. Chen, Prevalence and Risk Factor of Cognitive Impairment were Different between Urban and Rural Population: A Community-Based Study (4) 917–925
Taniguchi, S., see Royall, D.R. (2) 561–570
Taniguchi, S., see Royall, D.R. (2) 571–579
Tanskanen, A., see Saarelainen, L. (3) 809–818
Tanskanen, M., see Mäkelä, M. (1) 149–157
Tapadar, S., see Fà, M. (3) 707–721
Tárraga, L., see Pastor, P. (2) 343–352
Tavassoli, N., see Jacquin-Piques, A. (3) 671–680
Teich, A.F., see Fà, M. (3) 707–721
Terpstra, E., see Pan, Y. (1) 1–12
Thalamuthu, A., see Wu, H.Z.Y. (3) 755–766
Thatcher, G.R.J., see Fà, M. (3) 707–721
Tiihonen, J., see Saarelainen, L. (3) 809–818
Tischkau, S.A., see LeVault, K.R. (2) 301–316
Tolppanen, A.-M., see Saarelainen, L. (3) 809–818
Tong, Y., see Pan, Y. (1) 1–12
Tosto, G., S.E. Monsell, S.E. Hawes, G. Bruno and R. Mayeux, Progression of Extrapyramidal Signs in Alzheimer’s Disease: Clinical and Neuropathological Correlates (4) 1085–1093
Touchon, J., see Bouc, R.L. (4) 1075–1083
Touchon, J., see Gabelle, A. (4) 1135–1141
Triggiani, A.I., see Lizio, R. (1) 159–177
Triplett, J.C., A.M. Swomley, J. Cai, J.B. Klein and D.A. Butterfield, Quantitative Phosphoproteomic Analyses of the Inferior Parietal Lobule from Three Different Pathological Stages of Alzheimer’s Disease (1) 45–62
Tsai,C.-L., see Mehta, H.B. (2) 423–432
Tsolaki, M., see Sattlecker, M. (4) 1105–1114
Tsolaki, M., see Voyle, N. (3) 659–669
Tsui, W., see Spiegel, J. (1) 93–100
Tu, S., C.E. Leyton, J.R. Hodges, O. Piguet and M. Hornberger, Divergent Longitudinal Propagation of White Matter Degradation in Logopenic and Semantic Variants of Primary Progressive Aphasia (3) 853–861
Tudor, I.C., see Novak, G. (4) 1123–1134
Tuladhar, A.M., see van Uden, I.W.M. (3) 863–873
Tumminelli, G., I. Di Donato, V. Guida, A. Rufa, A. De Luca and A. Federico, Oculodentodigital Dysplasia with Massive Brain Calcification and a New Mutation of GJA1 Gene (1) 27–30
Turco, D.D., see Rüb, U. (4) 905–915
Unverzagt, F.W., see Kim, S. (4) 991–1003
Valentí, M., see Pastor, P. (2) 343–352
van der Flier, W.M., see Rosenberger, A.F.N. (4) 927–943
van der Flier, W.M., see Zwan, M.D. (4) 1115–1122
van der Holst, H.M., see van Uden, I.W.M. (3) 863–873
van der Vies, S.M., see Rosenberger, A.F.N. (4) 927–943
van Dijk, E.J., see van Uden, I.W.M. (3) 863–873
van Norden, A.G.W., see van Uden, I.W.M. (3) 863–873
van Uden, I.W.M., H.M. van der Holst, A.M. Tuladhar, A.G.W. van Norden, K.F. de Laat, L.C.A. Rutten-Jacobs, D.G. Norris, J.A.H.R. Claassen, E.J. van Dijk, R.P.C. Kessels and F.-E. de Leeuw, White Matter and Hippocampal Volume Predict the Risk of Dementia in Patients with Cerebral Small Vessel Disease: The RUN DMC Study (3) 863–873
Vanderstichele, H.M.J., see Barrado, L.G. (1) 187–199
Vázquez-Higuera, J.L., see Pastor, P. (2) 343–352
Veljanoski, R., see Zwan, M.D. (4) 1115–1122
Vellas, B., see Jacquin-Piques, A. (3) 671–680
Vellas, B., see Sattlecker, M. (4) 1105–1114
Vellas, B., see Voyle, N. (3) 659–669
Verret, L., see Bergeron, D. (3) 695–705
Villemagne, V.L., see Zwan, M.D. (4) 1115–1122
Volbracht, C., see Jul, P. (3) 783–795
Voyle, N., A. Keohane, S. Newhouse, K. Lunnon, C. Johnston, H. Soininen, I. Kloszewska, P. Mecocci, M. Tsolaki, B. Vellas, S. Lovestone, on behalf of the AddNeuroMed consortium, A. Hodges, S. Kiddle and R.J.B. Dobson, A Pathway Based Classi-fication Method for Analyzing Gene Expression for Alzheimer’s Disease Diagnosis (3) 659–669
Waern, M., see Bjerke, M. (3) 733–741
Wagner, M., see Koppara, A. (2) 547–560
Waldemar, G., see Nørgaard, A. (1) 211–220
Wallack, M., see Li, H. (1) 129–137
Wang, B., see Xie, H. (4) 961–969
Wang, C., see Shan, Y. (3) 829–844
Wang, D.-D., see Shan, Y. (3) 829–844
Wang, J., see Pan, Y. (1) 1–12
Wang, J.-Z., see Sun, X. (1) 63–72
Wang, K., see Xie, H. (4) 961–969
Wang, M., see Shi, Z. (2) 399–405
Wang, Q., see Sun, X. (1) 63–72
Wang, S., see Xie, M. (2) 353–363
Wang, V., see Kandiah, N. (2) 277–285
Wang, X., see Xie, M. (2) 353–363
Wang, X.-Y., see Li, F.-D. (1) 139–147
Wang, Y., see Pan, Y. (1) 1–12
Wang, Y., see Xie, H. (4) 961–969
Warren, J.D., see Clark, C.N. (1) 111–119
Wee, H.L., see Kandiah, N. (2) 277–285
Weekman, E.M. and D.M. Wilcock, Matrix Metalloproteinase in Blood-Brain Barrier Breakdown in Dementia (4) 893–903
Weimar, C., see Dlugaj, M. (4) 1031–1042
Weimar, C., see Winkler, A. (3) 797–807
Weinger, J.G., see Liu, G. (4) 971–990
Weiss, S.F.T., see Pinnock, E.C. (3) 645–657
Welch, P., see Bennett, J. (4) 1179–1187
White,L.R., see Berge, G. (2) 493–502
Whitehouse, P.J. and D.R. George, A Tale of Two Reports: What Recent Publications from the Alzheimer’s Association and Institute of Medicine say about the State of the Field (1) 21–25
Whitwell, J.L., see Madhavan, A. (3) 633–643
Wiendl, H., see Johnen, A. (3) 593–605
Wilcock, D.M., see Weekman, E.M. (4) 893–903
Williams, B., see Edwards, M. (1) 221–228
Williams, J.B., see Nafar, F. (1) 251–263
Williams, R., see Zwan, M.D. (4) 1115–1122
Williams, S., see Sattlecker, M. (4) 1105–1114
Wiltfang, J., see Koppara, A. (2) 547–560
Wiltfang, J., see Savastano, A. (1) 101–110
Winkler, A., C. Weimar, K.-H. Jöckel, R. Erbel, N. Dragano, M. Broecker-Preuss, S. Moebus, D. Führer-Sakel and M. Dlugaj on behalf the Heinz Nixdorf Recall Study Investigative Group, Thyroid-Stimulating Hormone and Mild Cognitive Impairment: Results of the Heinz Nixdorf Recall Study (3) 797–807
Winkler, A., see Dlugaj, M. (4) 1031–1042
Wirths, O., see Savastano, A. (1) 101–110
Wisniewski, T., see Spiegel, J. (1) 93–100
Wolfsgruber, S., see Koppara, A. (2) 547–560
Woodward, F.J., see Clark, C.N. (1) 111–119
Wu, H.Z.Y., K.L. Ong, K. Seeher, N.J. Armstrong, A. Thalamuthu, H. Brodaty, P. Sachdev and K. Mather, Circulating microRNAs as Biomarkers of Alzheimer’s Disease: A Systematic Review (3) 755–766
Wu, Y., see Shi, Z. (2) 399–405
Wyman, B.T., see Novak, G. (4) 1123–1134
Xia, L., see Geng, J. (4) 1161–1168
Xiao, Y.-Y., see Li, F.-D. (1) 139–147
Xie, H., C. Zhang, Y. Wang, S. Huang, W. Cui, W. Yang, L. Koski, X. Xu, Y. Li, M. Zheng, M. He, J. Fu, X. Shi, K. Wang, G. Tang, B. Wang and Y. Huo, Distinct Patterns of Cognitive Aging Modified by Education Level and Gender among Adults with Limited or No Formal Education: A Normative Study of the Mini-Mental State Examination (4) 961–969
Xie, M., Y. Han, Q. Yu, X. Wang, S. Wang and X. Liao, UCH-L1 Inhibition Decreases the Microtubule-Binding Function of Tau Protein (2) 353–363
Xie, S., see Chu, D. (2) 365–375
Xie, Z., see Shi, Z. (2) 399–405
Xu, J., see Spiegel, J. (1) 93–100
Xu, X., see Chan, Q.L. (1) 121–127
Xu, X., see Xie, H. (4) 961–969
Xu, Y.-X., see Shan, Y. (3) 829–844
Xue, F., see Liu, G. (4) 971–990
Yagita, Y., see Miwa, K. (2) 503–513
Yang, D. W., see Yoon, B. (1) 85–91
Yang, W., see Xie, H. (4) 961–969
Yao, X., see Sun, X. (1) 63–72
Ye, B.S., E.Y. Jang, S.Y. Kim, E.-J. Kim, S.A. Park, Y. Lee, C.H. Hong, S.H. Choi, B. Yoon, S.J. Yoon, H.R. Na, J.-H. Lee, J.H. Jeong, H.J. Kim, D.L. Na and S.W. Seo, Unstable Body Mass Index and Progression to Probable Alzheimer’s Disease Dementia in Patients with Amnestic Mild Cognitive Impairment (2) 483–491
Yener, G.G., see Lizio, R. (1) 159–177
Yin, X., see Chu, D. (2) 365–375
Yoo, Y., S.A. Shin, S. Park, J.-H. Lee, J.-H. Youn, Y.K. Kim and J.-Y. Lee, The Korean Size/Weight Attribute Test: A Semantic Knowledge Test for Korean Older Adults and Brain-Imaging Evidence (2) 377–386
Yoon, B., see Ye, B.S. (2) 483–491
Yoon, B., Y.S. Shim, H.-K. Park, S.A. Park, S.H. Choi and D. W. Yang, Predictive Factors for Disease Progression in Patients With Early-Onset Alzheimer’s Disease (1) 85–91
Yoon, S.J., see Ye, B.S. (2) 483–491
Youn, J.-H., see Yoo, Y. (2) 377–386
Young, S.A., see Shah, D.J. (2) 317–327
Yu, C., see Liu, J. (4) 1051–1064
Yu, L., see Han, S.D. (3) 845–851
Yu, Q., see Xie, M. (2) 353–363
Yuen, E., see Novak, G. (4) 1123–1134
Zetterberg, H., see Bjerke, M. (3) 733–741
Zetterberg, H., see Spiegel, J. (1) 93–100
Zhai, Y.-J., see Li, F.-D. (1) 139–147
Zhang, C., see Xie, H. (4) 961–969
Zhang, H., see Fà, M. (3) 707–721
Zhang, X., see Liu, J. (4) 1051–1064
Zhao, C., see Geng, J. (4) 1161–1168
Zheng, M., see Xie, H. (4) 961–969
Zhou, Y., see Tang, H.-D. (4) 917–925
Zhu, C.-Q., see Shan, Y. (3) 829–844
Zhu, H., see Li, H. (1) 129–137
Zhu, Y., see Shi, Z. (2) 399–405
Zhuo, J., see Liu, J. (4) 1051–1064
Zinkowski, R.P., see Spiegel, J. (1) 93–100
Zwan, M.D., V.L. Villemagne, V. Doré, R. Buckley, P. Bourgeat, R. Veljanoski, O. Salvado, R. Williams, L. Margison, A. Rembach, S.L. Macaulay, R. Martins, D. Ames, W.M. van der Flier, K.A. Ellis, P. Scheltens, C.L. Masters and C.C. Rowe for the AIBL study, Subjective Memory Complaints in APOE ɛ4 Carriers are Associated with High Amyloid-β Burden (4) 1115–1122
